Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 2/20 | 0.48 |
| ▸ | SYK | P43405 | 9/20 | 0.43 |
| ▸ | EGFR | P00533 | 5/20 | 0.42 |
| ▸ | ITK | Q08881 | 3/20 | 0.42 |
| ▸ | BMX | P51813 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | ULK1 | O75385 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1744616 | 0.90 | SYK (0.42) | PRKCQSYKEGFRITKBMX | |
| SCHEMBL1743594 | 0.82 | PRKCQ (0.58) | PRKCQSYKEGFRITKBMX | |
| SCHEMBL3494882 | 0.82 | SYK (0.62) | PRKCQSYKEGFRBMXBTK | |
| SCHEMBL3494055 | 0.82 | ULK1 (0.56) | PRKCQSYKBMXBTKULK1 | |
| SCHEMBL3497303 | 0.81 | PRKCQ (0.48) | PRKCQSYKEGFRITKBMX | |
| SCHEMBL3496386 | 0.81 | SYK (0.58) | PRKCQSYKEGFRBMXBTK | |
| SCHEMBL3496434 | 0.80 | SYK (0.51) | PRKCQSYKEGFRITKBMX | |
| SCHEMBL3497219 | 0.80 | PRKCQ (0.54) | PRKCQSYKEGFRITKBMX | |
| SCHEMBL3495899 | 0.79 | PRKCQ (0.59) | PRKCQSYKEGFRITKBTK | |
| SCHEMBL3495491 | 0.79 | ULK1 (0.58) | PRKCQSYKEGFRITKBMX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394951-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS INC. (US) | 2013-03-12 | — | — | US | claimed |
| EP-2387572-A2 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | Rigel Pharmaceuticals, Inc. (US) | 2011-11-23 | — | — | EP | claimed |
| US-8040334-B2 | Method of driving display device | 02MICRO INTERNATIONAL LIMITED (KY) | 2011-10-18 | — | — | US | claimed |
| WO-2010083207-A2 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-22 | — | — | WO | claimed |
| US-20100184755-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2010-07-22 | — | — | US | claimed |
| EP-3046560-B1 | STEM CELL MODULATION II | EPIAXIS THERAPEUTICS PTY LTD (AU) | 2021-01-06 | — | — | EP | disclosed |
| US-20200289437-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | EpiAxis Therapeutics Pty Ltd. (AU) | 2020-09-17 | — | — | US | disclosed |
| US-20200282010-A1 | IMMUNOGENIC COMPOSITIONS AND USES THEREFOR | EPIAXIS THERAPEUTICS PTY LTD (AU) | 2020-09-10 | — | — | US | disclosed |
| CN-111587120-A | Immunogenic compositions and uses thereof | 艾比克斯治疗私人有限公司 | 2020-08-25 | — | — | CN | disclosed |
| US-10736892-B2 | Stem cell modulation II | EpiAxis Therapeutics Pty Ltd. (AU) | 2020-08-11 | — | — | US | disclosed |
| US-20190192509-A1 | Stem Cell Modulation II | EpiAxis Therapeutics Pty Ltd. (AU) | 2019-06-27 | — | — | US | disclosed |
| US-10124001-B2 | Stem cell modulation II | UNIVERSITY OF CANBERRA (AU) | 2018-11-13 | — | — | US | disclosed |
| US-20130143875-A1 | Protein Kinase C Inhibitors and Uses Thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-20130143875-A1 | Protein Kinase C Inhibitors and Uses Thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-8394951-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS INC. (US) | 2013-03-12 | — | — | US | disclosed |
| CN-102292333-A | Protein kinase c inhibitors and uses thereof | — | 2011-12-21 | — | — | CN | disclosed |
| EP-2387572-A2 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | Rigel Pharmaceuticals, Inc. (US) | 2011-11-23 | — | — | EP | disclosed |
| US-8040334-B2 | Method of driving display device | 02MICRO INTERNATIONAL LIMITED (KY) | 2011-10-18 | — | — | US | disclosed |
| WO-2010083207-A2 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-22 | — | — | WO | disclosed |
| US-20100184755-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10736892-B2 | Stem cell modulation II | PRKCQ, PRKCI, PRKCG | PRKCQ 1/4885SYK 2245/4885EGFR 1255/4885 |
| US-20200282010-A1 | IMMUNOGENIC COMPOSITIONS AND USES THEREFOR | NFATC1, PRKCQ, PRKCH | PRKCQ 2/4885SYK 1306/4885EGFR 951/4885 |
| US-20200289437-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | PRKCQ, PRKCG, PRKCH | PRKCQ 1/4885SYK 2047/4885EGFR 1914/4885 |
| US-20130143875-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | PRKCQ 5/4885SYK 600/4885EGFR 2299/4885 |
| US-10124001-B2 | Stem cell modulation II | PRKCQ, PRKCI, PRKCG | PRKCQ 1/4885SYK 2245/4885EGFR 1255/4885 |
| US-20190192509-A1 | Stem Cell Modulation II | PRKCQ, PRKCI, PRKCG | PRKCQ 1/4885SYK 2245/4885EGFR 1255/4885 |
| US-20100184755-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | PRKCH, PRKCA, PRKCB | PRKCQ 5/4885SYK 600/4885EGFR 2299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.